P1vital Products Ltd are pleased to announce that the RTOC clinical study has been able to re-open recruitment across all 4 recruiting sites (based in the Netherlands, Germany, Spain and Greece) with new procedures in place to minimize risk of disease transmission.
Following successful data collection for the P1vital Cognitive Evaluation (VICOG) study, P1vital Products Ltd has donated £500 to Alzheimer’s Research UK. Dementia is a devastating disease which manifests itself through memory loss, mood changes and problems with communication, attention and thinking, amongst other symptoms. In the UK, it affects over 850,000 people, and costs the… Read more »
We are pleased to announce that P1vital Products Ltd has been awarded funding to help advance research into improving the treatment of depression and anxiety. P1vital Products Ltd will collaborate with a prestigious University in Canada to translate evidence gathered into effective, engaging and appropriate University student early intervention and prevention initiatives that are evaluable,… Read more »
Distractor helps you deal with lockdown trauma Playing video games during lock down can help with mental health problems according to top neuroscientists. And it can help frontline healthcare workers deal with the traumatic scenes confronting them daily as they fight to keep COVID-19 patients alive. We have developed DISTRACTOR in collaboration with Oxford based… Read more »
We are pleased to announce that P1vital Products Ltd has achieved Cyber Essentials certification. The Cyber Essentials Scheme is a Government-backed, industry-supported scheme to help organisations protect themselves against common online threats. To find out more, please click here.
Wallingford, UK, July 22, 2019 Research partners from pharma, academia, and SMEs have come together to form the Reward Task Optimisation Consortium (RTOC). Emerging from the ECNP Experimental Medicine Network and formally launched in April 2019, RTOC is a pre-competitive initiative which aims to advance the development of clinical tools to measure impaired motivation in… Read more »
i-spero® is being used as a part of Low mood, depression and anxiety walk in clinic in Faversham starting on Saturday 6 July. Click here to read more. Read more about i-spero®
Funding awarded to P1vital Products will help transform treatment of depression using digital technology.
(8 May 2019) P1vital Products (PPL) has, in partnership with Canterbury and Coastal CCG, University of Kent, and the mental health charity MIND, been awarded £815,506 by the UK’s innovation agency, Innovate UK, to advance research to improve the treatment of depression. The funding will enable a real-world evaluation of novel digital technology developed by… Read more »
New article on predicting antidepressant treatment response was published in November issue of European Neuropsychopharmacology which discusses the results of our Proof of Concept study conducted in the UK. To read full article, click here.
The Pharmaceutical Journal examines personalised treatment to depression including P1vital® PReDicT Test which is being used in PReDicT clinical study across 5 European countries. To read the full article, click here.